Table 2 Summary of medication use at the time of coronary catheterization between patients with normal versus abnormal endothelial-independent and endothelial-dependent microvascular function
|  | CFRAdn Ratio > 2.5 | CFRAdn Ratio ≤ 2.5 | p value | %ΔCBFAch > 50% | %ΔCBFAch ≤ 50% | p value |
|---|---|---|---|---|---|---|
Metformin, n (%) | 28 (35.0%) | 18 (36.7%) | 0.842 | 16 (31.4%) | 30 (38.5%) | 0.409 |
Thiazolidinedione, n (%) | 5 (6.3%) | 4 (8.2%) | 0.682 | 2 (3.9%) | 7 (9.0%) | 0.253 |
Sulfonylurea, n (%) | 12 (15.0%) | 9 (18.4%) | 0.617 | 7 (13.7%) | 14 (18.0%) | 0.522 |
Meglitinides, n (%) | 0 (0.0%) | 1 (2.0%) | 0.163 | 0 (0.0%) | 1 (1.3%) | 0.315 |
Dipeptidyl peptidase-4 inhibitors, n (%) | 2 (2.5%) | 0 (0%) | 0.165 | 1 (2.0%) | 1 (1.3%) | 0.763 |
Glucagon-like peptide 1 analog, n (%) | 3 (3.8%) | 0 (0%) | 0.088 | 2 (3.9%) | 1 (1.3%) | 0.337 |
Insulin, n (%) | 16 (20%) | 13 (26.5%) | 0.392 | 11 (21.6%) | 18 (23.1%) | 0.841 |
Dihydropyridines, n (%) | 15 (18.8%) | 8 (16.3%) | 0.726 | 9 (17.7%) | 14 (18.0%) | 0.965 |
Diltiazem, n (%) | 18 (22.5%) | 7 (14.3%) | 0.244 | 14 (27.5%) | 11 (14.1%) | 0.063 |
Statins, n (%) | 42 (52.5%) | 25 (51.0%) | 0.870 | 24 (47.1%) | 43 (55.1%) | 0.370 |
Ranolazine, n (%) | 2 (2.5%) | 1 (2.0%) | 0.866 | 2 (3.9%) | 1 (1.3%) | 0.337 |
ACE-Inhibitors or ARBs, n (%) | 36 (45.0%) | 25 (51.0%) | 0.506 | 21 (41.2%) | 40 (51.3%) | 0.260 |
Beta blockers, n (%) | 31 (38.8%) | 21 (42.9%) | 0.645 | 20 (39.2%) | 32 (41.0%) | 0.838 |
Aspirin, n (%) | 51 (63.8%) | 34 (69.4%) | 0.511 | 34 (66.7%) | 51 (65.4%) | 0.881 |
l-Arginine, n (%) | 4 (5.0%) | 2 (4.1%) | 0.809 | 4 (7.8%) | 2 (2.6%) | 0.169 |
Diuretics, n (%) | 22 (27.5%) | 21 (42.9%) | 0.074 | 14 (27.5%) | 29 (37.2%) | 0.249 |
Nitrates, n (%) | 22 (27.5%) | 16 (32.7%) | 0.535 | 17 (33.3%) | 21 (26.9%) | 0.437 |